Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Belimumab |
Synonyms | |
Therapy Description |
Benlysta (belimumab) is a monoclonal antibody that neutralizes B-cell activating factor (BAFF; TNFSF13B), potentially leading to increased NK-cell mediated lysis of tumor cells (PMID: 25710310). Benlysta (belimumab) is FDA approved for use in patients with systemic lupus erythematosus (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Belimumab | Benlysta | LymphoStat-B | Benlysta (belimumab) is a monoclonal antibody that neutralizes B-cell activating factor (BAFF; TNFSF13B), potentially leading to increased NK-cell mediated lysis of tumor cells (PMID: 25710310). Benlysta (belimumab) is FDA approved for use in patients with systemic lupus erythematosus (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|